

SDC 1: Predictors of Loss to Follow-up and Death among Children Starting Antiretroviral Therapy in Swaziland during 2004–2010 (N=2008)

	n	LTFU*								Death*								Attrition* (Death or LTFU)							
		Rate/ 100PY	HR	(95% CI)	p	AHR†	(95% CI)	p	Rate/ 100PY	HR	(95% CI)	p	AHR†	(95% CI)	p	Rate/ 100PY	HR	(95% CI)	p	AHR†	(95% CI)	p			
Down-referral																									
No	1,832	10.50	1.00	--	--	1.00	--	--	2.41	1.00	--	--	1.00	--	--	12.91	1.00	--	--	1.00	--	--			
Yes	176	3.77	0.42	(0.32-0.55)	0.001	0.40	(0.20-0.79)	0.019	1.44	0.54	(0.09-3.11)	0.402	1.18	(0.25-5.53)	0.785	5.21	0.44	(0.34-0.58)	0.001	0.46	(0.26-0.83)	0.020			
Site of ART initiation																									
Hub-only	612	8.15	1.00	--	--	1.00	--	--	3.64	1.00	--	--	1.00	--	--	11.79	1.00	--	--	1.00	--	--			
Hub with Spokes	1,077	10.98	1.79	(0.78-4.12)	0.129	0.77	(0.40-1.48)	0.348	1.58	0.43	(0.15-1.19)	0.084	0.46	(0.13-1.60)	0.168	12.56	1.31	(0.80-2.14)	0.208	0.72	(0.46-1.12)	0.111			
Spoke	319	4.04	0.61	(0.29-1.27)	0.141	0.65	(0.28-1.50)	0.234	1.87	0.33	(0.05-2.40)	0.208	0.36	(0.02-5.49)	0.370	5.91	0.51	(0.31-0.85)	0.020	0.62	(0.23-1.64)	0.258			
Age categories at ART initiation (years)																									
<2	614	14.05	1.00	--	--	1.00	--	--	4.32	1.00	--	--	1.00	--	--	18.38	1.00	--	--	1.00	--	--			
2–4	384	7.28	0.60	(0.38-0.95)	0.035	0.65	(0.42-1.01)	0.052	0.88	0.267	(0.12-0.57)	0.007	0.32	(0.14-0.70)	0.015	8.17	0.53	(0.39-0.71)	0.003	0.57	(0.43-0.76)	0.005			
5–14	1,010	7.85	0.65	(0.51-0.81)	0.005	0.58	(0.43-0.79)	0.007	1.84	0.492	(0.33-0.73)	0.006	0.43	(0.32-0.60)	0.002	9.69	0.61	(0.52-0.71)	<0.001	0.54	(0.43-0.67)	0.001			
Sex																									
Male	1,016	8.51	1.00	--	--	1.00	--	--	2.53	1.00	--	--	1.00	--	--	11.05	1.00	--	--	1.00	--	--			
Female	992	9.92	1.18	(1.06-1.31)	0.012	1.09	(0.99-1.21)	0.073	1.90	0.65	(0.46-0.93)	0.028	0.70	(0.47-1.04)	0.067	11.82	1.06	(0.92-1.21)	0.338	1.00	(0.87-1.15)	0.992			
WHO Stage																									
Stage I/II	552	8.28	1.00	--	--	1.00	--	--	0.90	1.00	--	--	1.00	--	--	9.14	1.00	--	--	1.00	--	--			
Stage III	939	8.93	1.16	(0.61-2.19)	0.581	0.98	(0.54-1.79)	0.925	2.05	2.90	(1.29-6.49)	0.021	2.19	(1.03-4.66)	0.045	10.99	1.31	(0.70-2.44)	0.308	1.10	(0.62-1.97)	0.681			
Stage IV	278	12.18	1.57	(0.92-2.66)	0.080	1.30	(0.80-2.12)	0.213	5.67	8.55	(3.64-20.08)	0.002	5.38	(2.34-12.35)	0.004	17.81	2.14	(1.07-4.25)	0.037	1.71	(0.95-3.06)	0.065			
Weight-for-age z-score																									
>-2	1,056	7.48	1.00	--	--	1.00	--	--	1.07	1.00	--	--	1.00	--	--	8.55	1.00	--	--	1.00	--	--			
<=-2	913	11.35	1.54	(1.00-2.37)	0.052	1.54	(1.03-2.30)	0.042	3.66	3.94	(2.53-6.14)	0.001	2.75	(1.81-4.17)	0.003	15.02	1.80	(1.19-2.74)	0.016	1.70	(1.20-2.42)	0.014			
CD4 %																									
≥20%	295	11.16	1.00	--	--	1.00	--	--	1.96	1.00	--	--	1.00	--	--	12.76	1.00	--	--	1.00	--	--			
10-<20%	639	8.27	0.84	(0.59-1.18)	0.193	0.93	(0.67-1.30)	0.570	1.77	1.41	(0.63-3.19)	0.281	1.48	(0.66-3.31)	0.221	10.28	0.95	(0.65-1.38)	0.693	1.05	(0.73-1.50)	0.728			
<10%	444	9.45	0.99	(0.62-1.58)	0.941	1.06	(0.65-1.73)	0.706	2.93	2.22	(0.84-5.82)	0.077	2.18	(0.74-6.47)	0.103	12.22	1.15	(0.79-1.67)	0.329	1.21	(0.82-1.79)	0.225			
Site Size (ART enrollees)																									
<1000	1693	10.41	1.00	--	--	1.00	--	--	1.96	1.00	--	--	1.00	--	--	12.37	1.00	--	--	1.00	--	--			
1000-1999	315	3.27	0.32	(0.19-0.54)	0.003	0.21	(0.11-0.40)	0.002	3.52	2.33	(1.12-4.86)	0.032	0.96	(0.56-1.66)	0.852	6.79	0.58	(0.40-0.84)	0.014	0.36	(0.22-0.57)	0.003			

Abbreviations: n, number of observations with complete data for the covariate; LTFU, loss to follow-up; HR, hazards ratio; AHR, adjusted hazards ratio; CI, confidence interval; ART, antiretroviral therapy; WHO, World Health Organization.

*Rates, HRs, AHRs, 95% CI’s, and p-values were derived from imputed data.

†All variables in this table were included in the multivariable model.